1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004; 137:486–495. PMID:
15013873.
Article
2. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003; 121:1621–1624. PMID:
14609922.
3. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 102:1640–1642. PMID:
6208888.
Article
4. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci. 1994; 35:3178–3188. PMID:
7519180.
5. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997; 81:154–162. PMID:
9059252.
Article
6. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113:363–372.e5. PMID:
16458968.
Article
7. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143:566–583. PMID:
17386270.
Article
8. Chan CK, Meyer CH, Gross JG, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina. 2007; 27:541–551. PMID:
17558314.
Article
9. CATT Research Group. Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364:1897–1908. PMID:
21526923.
Article
10. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1432–1444. PMID:
17021319.
Article
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1419–1431. PMID:
17021318.
Article
12. Gass JD. Serous retinal pigment epithelial detachment with a notch: a sign of occult choroidal neovascularization. Retina. 1984; 4:205–220. PMID:
6085179.
13. Gass JD. Pathogenesis of tears of the retinal pigment epithelium. Br J Ophthalmol. 1984; 68:513–519. PMID:
6204685.
Article
14. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009; 116:57–65.e5. PMID:
19118696.
Article
15. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005; 46:726–733. PMID:
15671306.
Article
16. Pauleikhoff D, Loffert D, Spital G, et al. Pigment epithelial detachment in the elderly: clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol. 2002; 240:533–538. PMID:
12136282.
17. Casswell AG, Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol. 1985; 69:397–403. PMID:
2408659.
Article
18. Inoue M, Arakawa A, Yamane S, Kadonosono K. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy. Retina. 2013; 33:990–997. PMID:
23446653.
Article
19. Parodi MB, Iacono P, Papayannis A, et al. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series. Am J Ophthalmol. 2013; 155:103–108.e2. PMID:
23022164.
Article
20. Bolz M, Michels S, Geitzenauer W, et al. Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol. 2007; 91:785–789. PMID:
17050580.
Article
21. Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina. 2007; 27:445–450. PMID:
17420696.
Article
22. Ach T, Hoeh AE, Ruppenstein M, et al. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Retina. 2010; 30:1420–1425. PMID:
20543764.
Article
23. Modarres M, Naseripour M, Falavarjani KG, et al. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina. 2009; 29:319–324. PMID:
19287288.
Article
24. Wu L, Arevalo JF, Roca JA, et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina. 2008; 28:212–219. PMID:
18301025.
25. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013; 120:1046–1056. PMID:
23352196.
Article
26. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci. 2006; 47:4569–4578. PMID:
17003454.
Article
27. Chan CK, Abraham P, Sarraf D. High-dose ranibizumab therapy for vascularized pigment epithelial detachment. Eye (Lond). 2012; 26:882–885. PMID:
22576827.
Article
28. Brown DM, Chen E, Mariani A, et al. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology. 2013; 120:349–354. PMID:
23131717.
Article
29. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113:623.e1. PMID:
16581423.
Article
30. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006; 26:257–261. PMID:
16508423.
Article
31. Feiner L, Barr EE, Shui YB, et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina. 2006; 26:882–888. PMID:
17031287.
Article
32. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006; 26:262–269. PMID:
16508424.
Article